ASCO 2020: Researchers underscore efficacy of pembrolizumab plus

Researchers at Fox Chase Cancer Center, along with an international team of investigators, have found that the use of pembrolizumab in combination with axiti

2022 ASCO® Annual Meeting: Updates on the Treatment of Advanced Renal Cell Carcinoma - Cancer Therapy Advisor

Exploring immunotherapy in colorectal cancer, Journal of Hematology & Oncology

Immunotherapy Guided by Immunohistochemistry PD-L1 Testing for Patients with NSCLC: A Microsimulation Model-Based Effectiveness and Cost- Effectiveness Analysis

Cancers, Free Full-Text

Clinical Trial Results National Cancer Institute

Five-Year Outcomes With Pembrolizumab Versus Chemotherapy for Metastatic Non–Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50%

Extended duration of treatment using reduced-frequency dosing of anti-PD-1 therapy in patients with advanced melanoma and Merkel cell carcinoma

Immunotherapy Guided by Immunohistochemistry PD-L1 Testing for Patients with NSCLC: A Microsimulation Model-Based Effectiveness and Cost- Effectiveness Analysis

Advances and key focus areas in gastric cancer immunotherapy: A comprehensive scientometric and clinical trial review (1999-2023)

Frontiers The association between aspirin use and immune-related adverse events in specific cancer patients receiving ICIs therapy: analysis of the FAERS database